Simonds et al 2021 -- Figures 2 and 3 (CyTOF mass cytometry of SB28 mouse gliomas)

Data corresponding to Figures 2 and 3 of http://doi.org/10.1136/jitc-2020-002181 Data were filtered on CD45-positive cells and processed using the PhenoGraph + FlowSOM analysis pipeline ("PhenoSOM") to segregate immune cell types into metaclusters and quantify their frequency across samples. The cluster IDs after Step 2 of the PhenoSOM pipeline are attached as CSV files (compressed as ZIP files). A key to link the FCS filenames to the cluster ID CSV files are also attached. Figure 2D: Comparing abundance of tumor-infiltrating leukocyte (TIL) subpopulations in dissociated intracerebral (i.c.) and subcutaneous (s.c.) SB28 tumors using the CyTOF mouse immune cell panel (Suppl Table S4). Figure 2E: Biaxial plots of representative raw CyTOF single-cell measurements of CD45, PD-L1, and CD206 on dissociated SB28 subcutaneous or intracerebral tumors. Only CD11b+ events are shown. Figure 2F: Mass cytometry data from SB28 subcutaneous or intracerebral tumors were manually gated as shown in (E) on CD11b+ TAMs expressing or lacking PD-L1, CD206, or MHC-II. Frequencies of TAMs expressing all possible permutations of these three markers were quantified. Figure 3C: Comparing abundance of immune subpopulations in dissociated subcutaneous SB28 tumors on Day 12 after ICI treatment versus isotype control treatment, using the mouse immune cell panel (Suppl Table S4). Figure 3D, comparing abundance of immune subpopulations in dissociated subcutaneous SB28 tumors on Day 27-29 versus Day 12.